tradingkey.logo
tradingkey.logo
Search

Charles River Laboratories International Inc

CRL
Add to Watchlist
177.620USD
-4.070-2.24%
Close 05/08, 16:00ETQuotes delayed by 15 min
8.56BMarket Cap
LossP/E TTM

Charles River Laboratories International Inc

177.620
-4.070-2.24%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.24%

5 Days

+7.14%

1 Month

+1.18%

6 Months

+5.69%

Year to Date

-10.96%

1 Year

+27.98%

Key Insights

Charles River Laboratories International Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 203.90.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Charles River Laboratories International Inc's Score

Industry at a Glance

Industry Ranking
12 / 384
Overall Ranking
89 / 4494
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Charles River Laboratories International Inc Highlights

StrengthsRisks
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -47.77, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.69M shares, decreasing 13.16% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 3.00 shares of this stock.

Analyst Rating

Based on 20 analysts
Buy
Current Rating
211.716
Target Price
+16.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Charles River Laboratories International Inc Info

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Ticker SymbolCRL
CompanyCharles River Laboratories International Inc
CEOFoster (James C)
Websitehttps://www.criver.com/
KeyAI